#USA #New York #Levi & Korsinsky #MoonLake #MLTX

MoonLake Immunotherapeutics Sued for Securities Law Violations

In recent developments, investors in MoonLake Immunotherapeutics, a biopharmaceutical company traded on NASDAQ under the symbol MLTX, have been put on alert for a class action lawsuit regarding allegations of securities fraud. The firm Levi & Korsinsky, LLP, known for its prowess in handling securities litigation, has initiated this lawsuit to protect shareholders who may have incurred losses during a specified period.

Class Action Overview

The class action lawsuit targets investors who purchased shares in MoonLake between March 10, 2024, and September 29, 2025. It focuses on claims that the company, its executives, or affiliates made materially misleading statements or failed to disclose key information regarding their primary drug candidate, SLK, and how it compares to BIMZELX, a competing pharmaceutical product.

Allegations Detailed

The complaint alleges several concerning points about MoonLake's communications: 1. Misleading Molecular Targets: It claims that SLK and BIMZELX share the same molecular targets, the inflammatory cytokines IL-17A and IL-17F, which may imply there is no comparative advantage in SLK's performance. 2. Questionable Structure Benefits: It asserts that SLK’s unique Nanobody structure might not deliver any superior clinical benefit over the traditional monoclonal antibody structure seen in BIMZELX. 3. Efficacy Claims Challenged: The filing also states that the supposed benefits of SLK, particularly the anticipated increased tissue penetration, would not necessarily correlate to enhanced clinical efficacy.

These allegations point to a troubling trend of potential miscommunication and inadequacies in corporate disclosures, which will be crucial for the court’s assessment of the case.

Next Steps for Investors

Investors who believe they have been negatively impacted have until December 15, 2025, to file their claims and possibly be appointed as lead plaintiffs in this class action. It is important to note that to qualify for any eventual compensation following a successful lawsuit, one does not have to serve actively as a lead plaintiff.

No Upfront Costs

According to Levi & Korsinsky, there are no fees or costs incurred by class members upfront. Thus, eligible investors can pursue their claims without financial risk, making it crucial for affected persons to engage with the firm promptly.

Levi & Korsinsky: A Proven Track Record

Levi & Korsinsky has established a strong reputation over the past two decades, effectively recovering substantial amounts for shareholders in similar cases. With a dedicated team of over 70 professionals, they specialize in complex securities litigation, aiming to deliver results for their clients.

How to Contact for More Information

If you are a shareholder of MoonLake and wish to participate in this class action lawsuit, you can reach out to Levi & Korsinsky, LLP, directly. Here are the main points of contact:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

• - Firm address: 33 Whitehall Street, 27th Floor, New York, NY 10004

For additional information, interested investors can also visit the firm's website or follow the link provided in the original announcement.

Conclusion

This unfolding situation surrounding MoonLake Immunotherapeutics serves as a stark reminder of the need for transparency in financial disclosures and the potential legal ramifications of misleading statements in the securities field. Investors are encouraged to stay informed and consider their options as this case progresses, with legal resources available to help navigate the complexities involved.